In the rapidly evolving world of oncology, researchers are constantly searching for "magic bullets"—treatments that can destroy cancer cells with surgical precision while leaving healthy tissue untouched. Today, a specific numerical designation is making waves in clinical circles: .
: Upon delivery, the stock vial should be stored at -20°C for long-term preservation. Repeated freeze-thaw cycles must be avoided as they break down the delicate immunoglobulin structures.
Developed by Orion Pharma, ODM-212 is a first-of-its-kind oral drug designed to tackle rare and aggressive cancers like mesothelioma. APAK-212
: When incubated with the membrane, the antibody binds precisely to the PAK1 bands (typically mapping around 68 kDa).
What should this article highlight? Share public link In the rapidly evolving world of oncology, researchers
Protecting expensive commercial real estate assets from basement flooding caused by severe storms or overwhelmed drainage networks.
The rise of multi‑drug‑resistant (MDR) Gram‑negative pathogens represents an urgent global health crisis. Here we report the design, synthesis, and comprehensive biological evaluation of , a 22‑residue cationic amphipathic peptide derived from a rational redesign of the native marine peptide APAK‑2 . AKAP‑212 exhibits broad‑spectrum bactericidal activity (MIC 0.5–4 µg mL⁻¹) against carbapenem‑resistant Acinetobacter baumannii , Pseudomonas aeruginosa , and Klebsiella pneumoniae while displaying negligible hemolysis (<2 % at 128 µg mL⁻¹) and low cytotoxicity toward mammalian cell lines (IC₅₀ > 200 µg mL⁻¹). Mechanistic studies indicate rapid membrane disruption via a toroidal pore model, confirmed by dye‑leakage assays, transmission electron microscopy (TEM), and solid‑state NMR. In a murine thigh infection model, a single sub‑cutanous dose of 5 mg kg⁻¹ reduced bacterial load by >3 log₁₀ CFU g⁻¹ relative to vehicle. These data position AKAP‑212 as a promising lead for development into a new class of therapeutic agents targeting MDR Gram‑negative infections. Repeated freeze-thaw cycles must be avoided as they
AKAP‑212 displayed potent bactericidal activity against all tested MDR Gram‑negative isolates. Time‑kill curves (Figure 1) showed >3 log₁₀ CFU reduction within 2 h at 4× MIC, confirming rapid killing kinetics.
The WHO’s 2023 priority pathogen list underscores carbapenem‑resistant A. baumannii , P. aeruginosa , and Enterobacteriaceae as critical targets for novel antimicrobials (World Health Organization, 2023). Conventional antibiotics are increasingly compromised by mechanisms such as efflux pumps, porin loss, and enzymatic degradation.